In phase I study in patients with advanced or metastatic solid tumors, brivanib demonstrated promising antiangiogenic and antitumor activity and manageable toxicity with most frequent serious toxic effects recorded being nausea, pyrexia, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations, and thrombocytopenia [80, 81]. The gene discussed is GPT; the disease is Thrombocytopenia.